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ABSTRACT 
 
Patients with end stage renal diseases (ESRD) requiring hemodialysis treatment experience 
cognitive impairment due to a variety of risk factors; most of which stem from chronic kidney 
disease (CKD) and the dialysis process itself. The purpose of this study was to assess changes in 
cognitive functioning in maintenance hemodialysis (MHD) patients during a standard 
hemodialysis (HD) session. MHD patients (n=12) were recruited from local dialysis clinics.  
Cognitive function was measured using a battery of tests from the CogState and Count Battle 
programs at 0, 1, and 3hrs into a standard HD treatment. In addition, quality of life and depression 
questionnaires, heart rate, blood pressure, relative blood volume (BV), hematocrit (HCT), and O2 
saturation data was collected for comparison. Significant declines were seen in cognitive domains; 
specifically long term memory measures over the course of a dialysis session (p<0.05). A trend 
toward significance was seen in the cognitive measure of working memory and the cardiovascular 
measure of mean arterial blood pressure. The change in several hemodynamic variables (mean 
arterial blood pressure, hematocrit, and relative blood volume) were correlated with the change in 
several measures of cognitive function. In addition, questionnaires evaluating quality of life and 
depression were correlated with measures of cognitive function. These findings suggest that 
cognitive impairment in hemodialysis patients is most likely due to a variety of cerebrovascular 
problems caused by CKD and the hemodialysis process itself. Further studies are needed to 
determine if other domains are also affected and to pinpoint the primary mechanisms behind these 
cognitive issues.  
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CHAPTER 1 
 
INTRODUCTION 
 
End stage renal disease (ESRD) patients who are required to receive MHD are at high 
risk for cognitive dysfunction due to various risk factors, which will be discussed in depth. 
Murray et al. (2007) found that 70% of MHD patients ages 55 years old and older exhibited 
moderate to severe cognitive impairment, yet few patients had a medically-documented history 
of impairment. Despite growing concerns regarding the prevalence and severity of cognitive 
impairment in the HD population, a paucity of literature exists. 
The risk factors hypothesized to contribute to cognitive dysfunction in this population can 
be broken into two categories: vascular and non-vascular. Cognitive function is mediated in part 
by cerebral blood flow, which is significantly affected by large vessel disease and small vessel 
disease (Pereira et al., 2005). The degradation of blood vessels in the brain limits blood flow, 
decreasing oxygen delivery to affected areas of the brain, and ultimately decreases oxidative 
metabolism. Large and small vessel disease can also be caused and/or exacerbated by other 
traditional cerebrovascular risk factors such as older age, hypertension, diabetes, and 
dyslipidemia. In addition, some nontraditional factors such as elevated plasma homocysteine 
levels, oxidative stress, and inflammation may also contribute to cognitive declines in this 
population (Pereira et al., 2005). 
HD treatment results in significant acute cognitive declines (Murray et al., 2007). This is 
thought to occur for several reasons including rapid changes in blood pressure occurring during 
regular HD treatment and the high prevalence of vascular disease in the population. Giang et al. 
(2012) looked at the relationship between blood pressure and cognition in HD patients by 
analyzing systolic and diastolic blood pressure, pulse pressure, and intradialytic change in 
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systolic blood pressure. They found that performance on cognitive tests, specifically executive 
function and processing speeds, was worse in those with low diastolic pressure and a high pulse 
pressure (Giang et al., 2012). 
The MHD process itself has been associated with increasing accounts of cerebral 
ischemia. A study of 151 MHD patients who had suffered acute strokes found that approximately 
34% of infarcts happened within 30 minutes after a dialysis session (Murray et al., 2013). Using 
Xenon inhalation scans and transcranial doppler sonography, researchers found a significant 
decrease in cerebral perfusion and blood flow velocity after HD compared to before (Murray et 
al., 2013). Similarly, others have shown decreased post-dialytic cerebral oxygen metabolism 
using PET scans (Murray et al., 2008). While research is limited, these suggest that HD 
treatment acutely reduces blood flow and, therefore, oxygen consumption and brain activity. 
Acute cognitive declines during HD are a significant barrier for clinicians, as much of the 
medical and dietary counseling patients receive occurs during treatment sessions, which may 
result in poorer adherence to recommendations. Indeed, a study by Kutner (2001) observed that 
at least 50% of HD patients are likely to be non-adherent with at least one aspect of their 
treatment plan. Moreover, compliance with diet and fluid intake recommendations may be as low 
as 35.5% and 40.3%, respectively (Lee et al., 2002). The low compliance commonly observed in 
HD patients may be, at least partially, attributed to receiving instruction during treatment, a time 
when cognitive functions such as memory and executive function are impaired. 
Current practice in Nephrology includes counselling patients during MHD treatment; 
however, this may not be the best course of action. Murray et al. (2007) observed significant 
declines in cognitive function during hemodialysis which may result in significantly poorer 
recommendation adherence due to decreased comprehension of medical prescriptions and advice 
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given by practitioners during this period. To date no study has investigated cognitive function 
over multiple time points during a single HD session and none have given a battery of cognitive 
tests. Most previous studies have assessed cognitive function on off-dialysis days, before and 
after an HD session, or at time points across multiple HD treatment sessions. It is necessary to 
complete testing at various time points during a single session to truly capture intradialytic 
changes and eliminate confounding factors that may occur from one HD treatment to the next. 
Also, a battery of tests needs to be constructed and validated to reduce time, patient burden and 
learning effect overall since traditional tests can take upwards of an hour to complete in order to 
capture all necessary domains. 
The study by Murray et al. (2007) has provided a sound rationale for this study and has 
created a stepping stone to build upon. In their study, cognitive assessments were done on four 
different dialysis days in an attempt to reduce patient burden due to the length of time associated 
with the cognitive assessments used. In addition, two of the four testing sessions were not 
completed in the dialysis setting, one being an hour before the dialysis session started and 
another 24 hours after the session had ended. This change in setting may result in drastically 
different results cognitively. 
Despite these concerns regarding the prevalence and clinical significance of cognitive 
deficits in HD patients, to date there are limited studies consistently showing these deficits are 
occurring and, in addition, the ones that have been conducted use traditional paper and pen 
cognitive tests that can be both time consuming and a burden to patients. It is the goal of this 
study to show that there is a significant proportion of the HD population that suffers from 
cognitive dysfunction during treatment and that a combination of various technologies can be 
used to illustrate this phenomenon while minimizing patient burden and time. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
Chronic Kidney Disease: Overview 
 
 Chronic kidney disease (CKD) is an inflammatory disorder that is both progressive and 
pervasive; it affects about 13% of adults in the United States and this number is continuously 
increasing (Coresh et al., 2007). In order to reach stage 5, which is also known as kidney failure, 
one must have a glomerular filtration rate (GFR) < 15 mL/min/1.73m and is normally treated 
with dialysis or transplantation. The two leading causes of CKD, diabetes and hypertension, 
currently afflict 26 million Americans are currently (United States Renal Data System, 2007). 
CKD is associated with a variety of disturbances in serum creatinine, blood urea nitrogen, urine 
protein, parathyroid hormone, calcium, phosphorus, and potassium and decreases in hemoglobin 
and serum albumin. Even the act of dialysis can lead to complications like large fluctuations in 
heart rate, blood pressure and flow, oxygen delivery which can lead to cognitive impairment. 
Being that MHD treatment is a complicated process that involves remembering a variety of 
medications, fluid and dietary instructions, and appointments with various clinicians, it is 
imperative to attempt to minimize any reductions.   
 
What Is Cognitive Dysfunction? 
 
 A patient can fall on wide spectrum of cognitive dysfunction. On the more severe end, 
decreases in cognition can be attributed to dementia; two of the most common forms being 
Alzheimer’s disease and vascular dementia. For the HD population, cognitive issues are more 
likely to be linked to vascular disease (Pereira et al., 2005). Dementia is defined as a general 
decline from a higher point of cognition and changes in behavior due to reductions in cognition 
that prevent normal daily functioning. In order for cognitive impairment to have occurred, a 
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deficit has to have occurred in at least two areas of cognition, including memory, executive 
functioning, attention, speed of information processing, motor abilities, or language (Madero et 
al., 2008). On the less severe end of the spectrum, mild cognitive impairment may be similar to 
dementia but differs in that daily life is not impacted as greatly. It is imperative to diagnose 
cognitive dysfunction early; if one has mild cognitive impairment they are ten times more likely 
to develop dementia compared to a healthy individual (Pereira et al., 2005).  
 
Prevalence of Cognitive Dysfunction in the Hemodialysis Population 
 
As previously stated, there are few detailed studies regarding cognitive function in the 
HD population and the prevalence of cognitive dysfunction has not been solidified. A study by 
Murray et al. (2006) assessed cognitive function in 338 hemodialysis patients aged 55 and older. 
These patients underwent a 45 minute battery to assess memory, executive function, and 
language. In terms of their impairment, 13.9% were determined to have mild impairment, 36.1% 
had moderate impairment, 37.3% had severe impairment, and only 12.7% had no impairment. In 
addition, only 2.9% had any history of impairment recorded. Other early studies have reported 
moderate rates of impairment but tend to exclude individuals with stroke, severe comorbidities, 
and older populations, which is a large proportion of the dialysis population. One study assessed 
80 individuals executive functioning and memory, finding severe impairment in 38% and 33% of 
them respectively (Murray et al., 2008). 
The lack of diagnosis of impairment in CKD and HD patients is pervasive. According to 
the 2006 USRDS annual data report, dementia is slightly higher in CKD populations at 7.6% 
than HD at 7%. As the age increases to 85 and up, the impairment also increases to 16.8% with 
CKD and 11.0% with HD (Murray et al., 2008). Many studies show that this impairment is not 
being detected by clinicians. This can be seen in the Murray study and was also seen in a study 
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by Sehgal (1997), where only 15% of the impaired patients had precious records indicating it. 
Previously cited studies have cognitive impairment levels around 37% (Murray et al., 2008) but 
data from the USRDS has this number at only 7.%. 
Dementia is not used by Medicare to classify the cause of hospitalizations which is 
astounding considering 1,012 of 308,793 admissions in 1997 were due to dementia (Pereira et 
al., 2005). It can be assumed that these numbers are an underestimate since dementia does not 
often directly lead to hospitalizations but may lead to the inevitable cause. A study conducted in 
Tokyo found that the one year incidence of dementia in older patients was 4.2%, but again, this 
number is under-representative of the true impact (Pereira et al., 2005). Some older studies have 
grazed the connection between kidney function or amount of dialysis and cognitive impairments. 
Uremia, along with the act of dialysis itself, has been associated with poor cognitive performance 
when compared to controls (Pereira et al., 2005).  It is clear that there is an underrepresentation 
of the true prevalence of cognitive dysfunction in the CKD and MHD populations.  
 
Brain Changes in the Hemodialysis Population 
 
Cognitive impairment may have a vast array of symptoms and underlying issues but 
ultimately they result from altered brain structure and metabolism. It has been observed via 
autopsy that stage 5 CKD patients who do not undergo dialysis present with acute necrosis of the 
granular layer of the cerebellar cortex, atrophy of the cerebellar cortex, and degradation of the 
brain stem (Pereira et al., 2005). A recent study by Kamata et al. (2000) analyzed the brains of 56 
HD patients and 42 controls finding that brain atrophy index and ventricular area index were 
higher in HD patients; atrophy increased as dialysis time increased. This would lead one to 
believe that either kidney failure or HD itself may be associated with cerebral atrophy and time 
on HD leads to greater atrophy. Savazzi et al. (2001) correlated high levels of cerebral atrophy 
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with a creatinine clearance of 10 mL/min or less in 77.5% of MHD patients. They concluded that 
early atherosclerosis and related hyperperfusion may be the cause of cerebral damage in uremia. 
Magnetic resonance imaging (MRI) has also been used to analyze the effects of CKD and 
HD on the brain, but in a limited capacity due to the expense and complication associated with 
using MRIs. Fazekas et al. (1995) compared 30 HD patients with 24 controls and found more 
cerebral atrophy in those undergoing HD. In addition, multiple white matter hyperintensities 
which show small-vessel disease, were prevalent in 33% of patients. It was also found that 
enlargement of the third ventricle and temporal horns were markers of cognitive impairment but 
not ischemic lesions (Fazekas et al., 1995). Another study found that focal white lesions were 
present in 56% of HD patients while only 27% of controls of a similar age presented with them 
(Geissler et al., 1995). Suzuki et al. (1997) used MRI to evaluate CKD patients and found white 
matter hyperintensities in a larger number than when compared to controls without kidney 
disease. These intensities were associated with hypertension, along with age and history of 
smoking as risk factors. Lastly, brain infarcts have been associated with two times the risk of 
developing dementia in HD patients (Pereira et al., 2005). 
Various studies have looked at the association between kidney failure and metabolic 
abnormalities in animals but not much has been done with humans. These studies have found 
kidney failure can lead to issues using adenosine triphosphate, increased brain calcium content, 
altered brain cell permeability, and amino acid abnormalities (Pereira et al., 2005). Clearly, it is 
necessary to see if these findings translate over to humans with kidney failure. It can be 
concluded from these studies that the brain in an individual with CKD or undergoing HD can 
incur severe damage and plays a direct role in cognitive impairment. 
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The Hemodialysis Process and Cognitive Dysfunction 
 
 A major concern that is starting to invade HD cognition talks is concerning the dialysis 
process itself and its potential contribution to impairment due to recurring cerebral ischemia. 
Toyoda et al. (2005) looked at 151 HD patients over the course of 22 years and found that 34% 
of infarcts happened within 30 minutes of a dialysis session. In addition, these infarcts were 15% 
more likely to occur in an HD patient than someone with normal kidney functioning. It was 
discovered that there were significant decreases in cerebral perfusion and blood flow velocity 
after dialysis compared to before using Xenon inhalation scans of cerebral circulation (Gottlieb 
et al., 1987). In addition, positron emission tomography (PET) scans have shown decreased 
cerebral oxygen metabolism and regional blood flow in HD patients (Kanai et al., 2001). 
 It has been proposed by Murray et al. (2008) that cerebral function declines due to acute 
fluid shifts and intravascular volume during dialysis causing cerebral edema and decreased 
cerebral blood pressure, blood velocity, and cerebral perfusion. It is within reason that if these 
factors increase the risk of ischemia and stroke, that the rise would be correlated with increasing 
dialysis dosage, or Kt/V, which was supported by the Murray study which found that a Kt/V > 
1.2 was associated with severe cognitive impairment. This raises the question of whether or not a 
slower ultrafiltration rate should be used along with longer dialysis sessions in order to minimize 
the risk of cerebral edema and recurrent ischemic episodes which ultimately lead to cognition 
issues. 
 
Cognitive Dysfunction: Risk Factors Overview 
 
 Community-based studies have been conducted in the general population in order to get 
an idea of what the risk factors for cognitive impairment are. These include older age, female 
gender, low education, race, diabetes and hypertension, lipids, stroke, anemia, head trauma, 
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obesity, inflammatory factors, and a few genetic markers such as APOE4 (Murray et al., 2008). 
Like many other health concerns, a healthy lifestyle can often protect against cognitive 
impairment. A diet made up of fruits, vegetables, and Omega 3 fatty acids and adequate levels of 
physical activity fall into this protective category (Murray et al., 2008). 
The HD and CKD populations can draw parallels to the general population with the 
addition of stroke, cardiovascular risk factors, uremia, anemia, metabolic disturbances, and 
hemodynamic instability all thought to play roles. A Health ABC study found that CKD 
attributed 10% of cognitive impairment risk that was not explained by demographics and 
comorbidities (Murray et al., 2008). Dementia has been found to be associated strongly with 
stroke, low education and an equilibrated Kt/V ≥ 1.2 in the CKD and HD populations (Murray et 
al., 2008). The HD population also has high rates of hypertension, 80%, and diabetes, 60%, 
elevated levels of inflammation, and cardiovascular/vascular events that can lead to cognitive 
impairment (Murray et al., 2008).  These vascular issues seems to have the highest correlation 
with cognitive impairment in the HD and CKD populations. 
 
Cognitive Dysfunction: Causes and Mechanics 
 
Vascular Risk Factors 
 The primary risk factor that may drive cognitive impairment in dialysis patients involve 
vascular issues. It has been demonstrated that cognitive functioning in older populations is 
connected to cerebral blood flow, and large/small vessel disease. As previously mentioned, older 
age, hypertension, diabetes, and dyslipidemia are traditionally recognized as risk factors (Pereira 
et al., 2005). There are other risk factors that could also play a role in cognitive impairment; 
these include plasma homocysteine (tHcy) levels, oxidative stress, and inflammation (Pereira et 
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al., 2005). All of these factors greatly affect cognition in the general population and may also 
relate to HD patients. 
 
Cerebral Risk Factors 
 It has been demonstrated that age, hypertension, diabetes, and dyslipidemia are risk 
factors for dementia in the general population; it has also been shown that hypertension and 
diabetes are risk factors for stroke (Pereira et al., 2005). There is limited data, however, relating 
these risk factors to cognitive impairment in the HD population. A study by Sehgal et al. (1997) 
looked at 336 HD patients and found that a variety of factors including age, male sex, race, 
education, and the presence of cerebrovascular disease or depression were correlated with lower 
Mini–Mental State Examination (MMSE) scores. Further analysis is required to narrow the 
scope of these factors. 
 
Other Potential Vascular Risk Factors 
 It has been suggested that factors such as plasma tHcy levels, increased oxidative stress, 
and inflammation increase the risk of developing cognitive impairment. Traditionally, dialysis 
patients present with elevated tHcy levels, greater than 1.87 mg/L, compared to the general 
population. This can be seen with 85% of the HD population having elevated levels while only 
10% of the general population have these high levels (Pereira et al., 2005). It has been theorized 
that tHcy levels effect cognitive impairment via a prothrombotic affect leading to large/small 
vessel disease, a neurotoxic effect via the N-methyl-D-aspartate receptor leading to cell death, 
and conversion of tHcy to homocysteic acid leading to an excitotoxic effect on neurons (Pereira 
et al., 2005). Previous studies that have associated tHcy with cognitive impairment in the general 
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population. One of these showed that increased tHcy levels are predictive of Alzheimer’s disease 
during an 8 year follow up of 1,092 patients (Seshadri et al., 2002). 
 Oxidative stress and inflammation are pervasive issues in the HD population that lead to 
a variety of other health issues. HD patients undergo oxidative stress due to reduced antioxidants 
and increased pro-oxidant factors (Locatelli et al., 2003). Oxidative stress and inflammation are 
known to contribute to athlerosclerotic cardiovascular diseases, but to our knowledge, no study 
has been conducted connecting them to cognitive impairment. In the general population, Berr 
(2002) studied 1,611 healthy adults and showed that those with higher thiobarbituric acid 
reactant substances (TBARS), which indicate lipid peroxidation, were 2.3 times more likely for 
cognitive decline. In a study conducted by Schmidt et al. (2002), it was discovered that midlife 
C-reactive protein levels predicted the development of vascular dementia and Alzheimer’s 
disease. These studies may not have been conducted in HD patients, but they lead one to believe 
that they may be associated with the mechanics of cognitive impairment in the population. 
 
Nonvascular Risk Factors 
 Nonvascular risk factors such as anemia, erythropoietin (EPO) deficiency, and 
parathyroid hormone activity may also play a role in cognitive impairment. The majority of 
dialysis patients are anemic due to lack of erythropoietin production by the kidneys (Pereira et 
al., 2005). This may lead to cognition issues because a lower hematocrit leads to decreased brain 
oxygenation. A decreased hematocrit leads to a correction resulting in abnormally high cerebral 
blood flow carrying uremic toxins, and this higher blood flow may cause increased intracranial 
pressure and brain edema (Pereira et al., 2005). It has been demonstrated in animals that EPO has 
a neuroprotective quality and is upregulated during hypoxic events (Sun et al., 2004). It is 
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unknown, however, if EPO deficiency is a risk factor of cognitive impairment without anemia. 
Parathyroid hormone (PTH) is not well understood but may have cognitive implications. In a 
uremic patient, when a patient has increased PTH levels the calcium in tissues such as the brain 
and blood vessels is also elevated. This may indicate that PTH acts as a facilitator for calcium 
movement into tissues which would then affect cognition (Fraser, 1988). Since calcium is an 
integral factor in neurotransmission in the central nervous system and intracellular enzyme 
systems, it could mean that increased brain calcium content could disrupt either of these and lead 
to cognitive issues. 
 
Cognitive Dysfunction: Impact on Outcomes 
 
 One of the most important aspects associated with HD and cognitive impairment is the 
long-term effects and ultimately expected outcomes. Dementia can often lead to a multitude of 
adverse outcomes. Hospitalizations are increased in those with dementia in the USRDS 
population (“United States Renal Data System”, 2005). One study conducted by the USRDS 
found that when comparing CKD patients with dementia to those without, the lifespan after 
starting dialysis was 1.09 and 2.7 years, respectfully (Kurella et al., 2006). In addition, death was 
1.48 times as likely when dementia was present. Dementia also had a rather large impact on 
financial burden with an extra $19,100 being spent by Medicare in 2002 over a year on HD 
patients with dementia compared to those without (“United States Renal Data System”, 2005). 
By reducing or removing cognitive deficits in the MHD population, one would increase the 
average lifespan of a MHD patient and reduce the financial burden associated with care. 
 Cognitive impairment can have widespread negative effects on those afflicted by it. 
MHD patients may have trouble understanding all the complicated aspects of their care including 
their dialysis sessions, diet, fluid restrictions, rationale behind their clinicians’ decisions, and 
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even negate their ability to provide informed consent. Cognitive dysfunction leads to diminished 
quality of life. Many studies have shown that HD patients have a reduced emotional well-being 
and psychological functioning (Bremer et al., 1995). These studies have not examined how this 
may connect to cognitive functioning.  
 
Cognitive Dysfunction: Depression 
 
 Compiled with extrinsic factors that may also contribute, the HD process and cognitive 
impairment resulting from it may also cause depression. Agganis et al. (2010) measured a battery 
of neurocognitive tests and associated them with depression scores via the Center for 
Epidemiologic Studies Depression Scale (CES-D) in 241 MHD patients and found that the 
patients with higher depression scores performed worse on processing speed and executive 
functioning. Additionally, Ku et al. (2012) found that depression in those with chronic renal 
failure and uremic peripheral polyneuropathy was affected by a variety of psychological factors 
illustrated by the Mental Component Summary. Taken together, these results suggest that 
depression is another co-morbidity in HD patients associated with cognitive function.  
 
Counters to the Argument 
 There are a few studies that have refuted some of the relationships that have been 
proposed to exist between dialysis and cognitive impairment. Dialysis adequacy, an average of 
Kt/V assessments, and cognitive functioning, a neurocognitive battery during the first hour of 
dialysis, were examined by Giang et al. (2011). In opposition to previous studies, they found that 
reductions in Kt/V were not associated with impaired cognition. As previously stated, various 
risk factors have been proposed, if not shown, to be connected to cognition. Tamura et al. (2010) 
concluded that cognitive impairment is common but is not associated with many ESRD and 
 14  
 
dialysis associated risk factors; these factors include urea clearance, nutritional markers, 
hemodynamic measures, and anemia. These studies have only looked at a fraction of the possible 
risk factors and none have focused on the vascular and cerebrovascular factors that reduce blood 
flow, cerebral oxygenation, and ultimately cerebral metabolism. 
 
Use of Laptop/Tablet for Assessment 
 Until very recently, cognitive assessments have been conducted with a “paper and pen” 
method that is both time consuming, lacks repeatability, and is fraught with human error. There 
is currently a push to incorporate more technology into cognitive assessments with positive 
results. One specific program is CogState, a series of predefined batteries that take place on a 
laptop. Previous research has validated the four standard psychological paradigms that have been 
defined within CogState’s brief battery by comparing healthy adults to individuals with mild 
head injury, schizophrenia, and AIDS dementia complex (Maruff et al., 2009). They concluded 
the program to have strong correlations in the measures of processing speed, attention, working 
memory, and more (Maruff et al., 2009). Lim et al. (2012) further validated CogState by 
comparing healthy older adults and patients with mild cognitive impairment, finding that it could 
be used to screen for Alzheimer’s related cognitive changes. Other similar computer based 
batteries have proven effective in detecting mild cognitive impairment in the elderly (Dwolatzky 
et al., 2003). CogState has also been used in association with Alzheimer’s neurodegenerative 
imaging markers. Mielke et al. (2014) found that CogState showed as much variance in 
neuroimaging measures as standard neuropsychological tests. Specifically, slow reaction times in 
tasks such as the Identification and One Back were associated with FDG-PET hypometabolism 
and slower times in the Groton Maze Learning were associated with smaller hippocampal 
volumes; both of which are early markers of Alzheimer’s disease (Mielke et al., 2014). Even 
 15  
 
though CogState has not been validated in the dialysis population, evidence demonstrates that it 
will still be able to detect any performance deficiencies like it can with similar populations, i.e. 
Alzheimer’s and dementia. 
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CHAPTER 3 
 
METHODOLOGY 
 
Subjects 
Twelve patients on MHD (4 females, 8 males) were recruited from the Champaign-
Urbana Dialysis Clinic (Champaign, IL). Patients were screened for eligibility by administering a 
health and medical history questionnaire. All participants gave written informed consent and this 
study was approved by the University of Illinois Institutional Review Board.  Inclusion/exclusion 
criteria for patients included the following: 1) Subjects must have received MHD treatment at 
least 3 days per week. 2) Subjects must be between 20-75 years of age. 3) Patients on dialysis 
treatment for < 3 months were excluded due to physiological changes that typically occur at the 
onset of dialysis. 4) No previously diagnosed case of any cognitive dysfunction including but not 
limited to: dementia, amnesia, Alzheimer’s disease, Parkinson’s disease, and epilepsy. 
 
Study Design 
Following recruitment and screening, eligible participants completed two pre-testing 
questionnaires, the Kidney Disease Quality of Life Instrument (KD-QOL) and Center for 
Epidemiologic Studies Depression Scale (CES-D). Participants were given test instructions and 
allowed to acclimate to the tests prior to the testing day.  
Twelve participants aged 20-75 years underwent a battery of cognitive tests at three time 
points (BASE, 1HR, and 3HR). The 1HR time point was chosen because it has been 
demonstrated to represent the time point during dialysis with the greatest cognitive deficits based 
on previous research (Murray et al, 2007). The participants were prepared for testing 15 minutes 
prior to the first test. 
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On the testing day, each participant arrived 30 minutes prior to their regularly scheduled 
treatment. During this time, the participants were reminded of the instructions for the various 
tests. A battery of cognitive tests were completed as described below at the start, 1hr and 3hrs 
into the HD treatment. 
 
Cognitive Testing 
Cognitive assessments included four tests from the CogState program carried out via 
laptop (“Home - CogState”, 2013): the chase task, the detection task, the identification task, and 
the international shopping task with a delayed recall; and the Count Battle program, carried out 
via iPad.  
 
The Chase Task 
The Chase task takes approximately thirty seconds (based on average time in healthy 
volunteers) and measures visual motor function. In this task, the participant was shown a 10 x 10 
grid of tiles on the computer. The participant was asked to tap the blue tile in the top left corner 
of the grid with the cursor. As the target moved, the participant ‘chased’ it by tapping on the tiles 
one at a time. The subject could not move diagonally and could not skip a tile. If the participant 
made a mistake, they needed to go back to the last correct tile. For this task, the primary outcome 
was the total number of correct moves made per second, a higher score meant a better 
performance (Chase Task, n.d.).  
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The Detection Task 
The next task was the detection task, which takes approximately two minutes to complete 
and tests psychomotor function, as well as speed of processing. Speed of processing measures 
how an individual can evaluate and act upon a stimulus (“Home - CogState”, 2013). The prompt 
for this task was: “Has the card turned over?” Initially, a playing card appeared on the screen. 
The card then flipped over so it was face up. As soon as it did, the participant needed to press the 
“Yes” button on the mouse. The card went to the back of the pack and the participant pressed the 
“Yes” button as soon as the next card flipped over until the practice ended. The participant 
practiced until they reached the required number of responses, or until the practice period 
expired. The real test then followed, which was the same as the practice. The primary outcome 
measure for this task was speed of performance, or the mean of the log10 transformed reaction 
times for correct responses where a lower score meant a better performance (Detection Task, 
n.d.).  
 
The Identification Task 
The third task was an identification task, which takes approximately two minutes and 
assesses visual attention and vigilance. This task is relevant given the education and counselling 
MHD patients during treatment as well as the visual attention needed to get home post HD. The 
initial prompt for this task was: “Has the card turned over?” Initially, a playing card appeared on 
the screen. The card then flipped over so it was face up. As soon as it did this the subject needed 
to decide whether the card was red or not; if it was red he/she pressed “Yes”, if it was not red 
he/she pressed “No”. Just like the Detection Task, a practice session was first followed by the 
real test. The primary outcome measure for this task was speed of performance, or the mean of 
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the log10 transformed reaction times for correct responses where a lower score meant a better 
performance (Identification Task, n.d.).  
 
The International Shopping List and Delayed List Tasks 
The International Shopping List Task and the Delayed version take approximately 7 
minutes total due to it being done twice; once at the beginning of each testing session (5 minutes) 
and then a shorter version at the end of the cognitive tests for a delayed recall (2 minutes). In this 
instance, verbal learning and memory are the domains that are measured; specifically working 
memory and longer term memory (“Home - CogState”, 2013). For the initial task, the test 
supervisor read the list of words, 16 total, as they appeared on the computer screen at a rate of 
one word every two seconds. When the test supervisor finished they asked: “Tell me as many of 
the items on the shopping list as you can remember?” As the participant recalled words, the test 
supervisor clicked the appropriate button on the screen. If the participant said a word that was 
not on the list, the test supervisor clicked “Other Word”. If the participant repeated a word, the 
test supervisor clicked the word as many times as the word was said. This is repeated two more 
times before moving onto the next Task. The primary outcome for this task was the total number 
of correct responses made in remembering the list on three consecutive trials at a single session; 
a higher score meant a better performance (International Shopping List Task, n.d.). For the 
Delayed International Shopping List task, the participant was not read the list again but was 
simply asked to recall the previously read list. Again, the primary outcome for this task was the 
total number of correct responses made in remembering the list but this time after a delay; a 
higher score meant a better performance (International Shopping List Task – Delayed, n.d.). It is 
important to note that at the three different time points the list differed, i.e. 16 different words. 
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Count Battle 
The Count Battle program uses the traditional Trail Making Test (parts A and B) but 
simplifies its delivery by incorporating a tablet. Normally, the task requires a subject to connect 
25 consecutive dots on a sheet of paper or computer screen and the test taker needs to connect 
them in sequential order. In this program, participants connected 16 numeric dots in 
chronological order or 8 numeric and 8 alphabetic dots in the order: 1, A, 2, B, 3, C, etc. On the 
very easy setting the dots were static. On the easy setting, the dots would randomly shift position 
on the screen in set intervals. This was the same for the Normal easy setting with faster intervals. 
If a mistake was made, the participant needed to go back one dot; for example a mistake at 8 
would set the participant back to 7. Tests were carried out at two different settings (numeric and 
alpha numeric) at three difficulties (very easy, easy, and normal) for a total of six tests per time 
point. 
 
Cardiovascular Measurements 
Research staff measured brachial blood pressure using the automatic digital blood 
pressure monitor in duplicate at each of the three cognitive testing points. If these two 
measurements were within 10% of each other, the average of the two measurements was taken as 
the final recorded blood pressure.  If not, a third measure was taken, and the two closest 
measures were averaged. These measures were then used to calculate mean arterial blood 
pressure (MAP) for analysis. 
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Blood collection 
All blood draws explained below took place at the clinic during regular dialysis sessions, 
with the assistance of the nurses and dialysis technicians. Because all dialysis patients have 
arterial lines in them during their dialysis treatment, the following blood collection will not 
require additional needle sticks. At time point zero at the clinic, subjects will have blood drawn 
at 2 time points: immediately prior to the initiation of dialysis treatment and 3 hours into 
treatment (~ 40ml total). The whole blood samples will be centrifuged and separated into 4 vials 
(500 µl aliquots) that will be stored at -80˚C for future analysis. The blood that is collected will 
be centrifuged to collect serum and plasma, which will then be aliquoted and stored at -80C until 
analyzed. Plasma and serum samples will be used to measure circulating levels of lipids and 
proteins related to co-morbidities in hemodialysis patients, including markers of inflammation 
and oxidative stress.  
 
Relative Blood Volume and Hematocrit 
The Critline is a regular part of dialysis treatment at the C-U clinic.  The Critline non-
invasively measures hematocrit, relative blood volume, and oxygen saturation in real time.  A 
disposable blood chamber will be added to the dialysis machine by a trained staff member of the 
CU Dialysis Clinic.  As blood travels through this chamber hematocrit and oxygen saturation are 
measured by the absorbance and scattering of light.  The hematocrit value is then used to 
estimate the blood volume relative to the start of the dialysis session.  
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Questionnaires 
As previously mentioned, the KD-QoL and CES-D questionnaires were delivered prior to 
testing but within a week of the testing date.  The KD-QoL provides individual scores for 10 
metrics related to quality of life in CKD patients, while the CES-D provides a single depression 
score based on an analysis of 20 items.   
 
Statistical Analyses 
All statistical analyses were performed using SPSS 22.0 software (IBM, Armonk, NY) 
and significance was based on a two-tailed alpha value of 0.05.  Data was expressed as mean ± 
standard deviation (SD) unless otherwise stated.  Data was analyzed using repeated measures 
analysis of variance (ANOVA to compare different time points of cognitive function test. When 
ANOVA indicated a significant main effect of time, a protected LSD was performed to 
determine differences between time points. ). Pearson correlations were performed to determine 
the relationships between parameters of cardiovascular variables, questionnaires, and cognitive 
function.   
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CHAPTER 4 
 
RESULTS 
 
Patient Characteristics 
Patient characteristics can be seen in Table 1. The average age for the patients in this 
study was 45±14 years of age. It can be seen that a relatively high proportion of diabetes (33%) 
and hypertension (58%) were present. The majority of participants were African American 
(75%) followed by Caucasian (17%). 
 
Cognitive Functioning: CogState  
The cognition measurements for the five CogState tests are shown in Table 2. For the  
delayed recall of the International Shopping List, there was a main effect of time, indicating a 
reduction in long term memory over the course of a dialysis session (p=0.026). There was also a 
trend for a reduction in the immediate recall component of the international shopping list over 
time (p=.146), indicating a potential decline in verbal learning and working memory. There were 
no significant differences in the Chase, Detection, or Identification tasks over time. 
 
Cognitive Functioning: Count Battle 
 The cognition measurements for the six Count Battle tests are show in Table 3. There 
was no significance detected for any of these tests. 
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Cardiovascular Measurements 
 The cardiovascular measurements, which included heart rate and MAP, are shown in 
Table 4. There was no change in heart rate during hemodialysis; however, a trend towards a 
reduction in MAP was observed during the dialysis treatment (p=.090). 
 
Correlation Analysis 
 Results from the correlation analysis that we conducted can be found in Tables 5-7. 
There was a significant correlation between the change in the Identification Task on the Cogstate 
program and the change in mean arterial blood pressure. In addition, there was a trend for a 
correlation between change in hematocrit and change in the International Shopping List Task (p= 
0.15) and Delayed international Shopping List tasks (p= 0.13) However, no other correlations 
between cognitive and hemodynamic measures were detected (Table 5).  
Significance correlations were seen between the Chase, Detection, and Identification 
tasks and the KD-QoL’s measures of Work, as well as between the Detection Task and the KD-
QoL’s measure of Support (p<.05). However, no other correlations were found between the other 
cognitive tasks and KD-QoL metrics (Table 6).   
Data from the CES-D indicated that 33% of the patients in the study had signs of 
depression.  However, there were no significant correlation between the CES-D score and any 
hemodynamic or cognitive variables (Table 7).  
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Table 1. Subject Characteristics 
  
Demographics 
Total 
(n=12) 
Age (years) 45 (14) 
Gender (male/female) 8/4 
Race (%) 
      African American 
      Caucasian 
      Other 
 
75 
17 
8 
Diabetes (%) 33 
Hypertension (%) 58 
For age, data expressed as mean ± SD    
 
 
Table 2. CogState Cognition Measurements 
  
Measure 
  P-
Value 
 
Baseline 1 Hour 3 Hour   
International 
Shopping List 
Task (# of 
correct 
responses) 
22.18(4.51) 19.18(4.14) 20.00(6.44) 0.146  
Delayed 
International 
Shopping List 
(# of correct 
responses) 
7.81(2.09) 6.09(2.81) 5.45(3.42) 0.026  
Chase Task 
(moves/sec) 
.8512(.4113) .8483(.4475) .7725(.4287) 0.330  
Detection Task 
(log10(ms)) 
2.67(.15) 2.68(.14) 2.67(.10) 0.917  
Identification 
Task 
(log10(ms)) 
2.85(.09) 2.85(.09) 2.87(.11) 0.177  
Data expressed as mean ± SD    
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Table 3. Count Battle Cognition Measurements 
Measure 
 
Baseline 1 Hour 3 Hour P-
Value 
Trails A- Very Easy (s) 31.08(19.18) 25.95(13.59) 28.31(17.86) 0.185 
Trails A- Easy (s) 65.64(79.12) 65.78(80.03) 64.52(80.54) 0.919 
Trails A- Normal (s) 132.48(114.72) 108.07(110.96) 128.62(119.75) 0.341 
Trails B- Very Easy (s) 58.87(47.39) 49.14(31.50) 47.01(29.58) 0.421 
Trails B- Easy (s) 92.55(81.20) 92.88(88.23) 100.67(89.89) 0.652 
Trails B- Normal (s) 176.70(117.25) 161.98(116.50) 155.47(117.08) 0.467 
Data expressed as mean ± SD    
 
 
Table 4. Cardiovascular Measurements 
Measure 
 
Baseline 1 Hour 3 Hour P-
Value 
Heart Rate (bpm) 80(10) 81(11) 84(14) 0.244 
Mean Arterial Blood 
Pressure (mmHg) 
105(19) 99(19) 92(16) 0.090 
Data expressed as mean ± SD    
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Table 5. Correlation between the change (Δ) in Cognition and Hemodynamic Measures from 
the Baseline to the 3 Hour timepoint 
 ΔMAP Relative 
ΔMAP 
ΔHCT ΔBV ΔO2 SAT 
ΔCogState 
 
     
International 
Shopping List 
Task 
 
.291 .414 -.526 .337 -.086 
Delayed 
International 
Shopping List 
 
.008 .831 -.512 .271 .165 
Chase Task 
 
.401 .206 -.051 -.019 -.076 
Detection 
Task 
 
.328 .374 -.003 -.033 -.088 
Identification 
Task 
 
.624* .065 .476 -.423 .341 
ΔCount 
Battle 
 
     
Numeric Very 
Easy 
 
.120 .101 -.068 -.285 -.140 
Numeric Easy 
 
-.184 -.101 .194 -.176 .362 
Numeric 
Normal 
 
-.279 -.278 -.230 .012 .294 
Alpha 
Numeric Very 
Easy 
 
-.216 -.260 -.294 .436 -.349 
Alpha 
Numeric Easy 
 
.226 .146 .280 -.102 .323 
Alpha 
Numeric 
Normal 
-.075 -.036 .399 -.294 .378 
*p<.05 
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Table 6. Correlations between Baseline Cognition Measures and KD-QoL Measures 
 
 Burden Cognitive Social Symptom CKD 
Effects 
Sleep Support Work Satisfaction Staff 
Encouragement 
ΔCogState 
 
          
International 
Shopping List 
Task 
 
-.454 -.353 -.327 -.378 -.477 -.078 -.239 .216 -.103 -.243 
Delayed 
International 
Shopping List 
 
-.192 -.348 -.136 -.168 -.199 .217 -.108 .227 .126 -.067 
Chase Task 
 
-.389 .192 .240 -.002 -.515 .035 -.438 .717* .324 .107 
Detection 
Task 
 
.443 -.422 -.159 -.151 .432 -.021 .619* -.632* -.220 -.103 
Identification 
Task 
 
.405 -.211 -.116 .039 .446 .098 .486 -.626* -.035 .085 
ΔCount 
Battle 
 
          
Numeric Very 
Easy 
 
.255 .171 -.131 .278 .439 -.117 .230 -.452 .008 .291 
Numeric Easy 
 
.486 .212 .149 .259 .298 .080 .204 -.369 .239 .275 
Numeric 
Normal 
 
.052 -.019 -.219 .140 .362 -.210 .322 -.300 -.154 .272 
Alpha 
Numeric Very 
Easy 
 
.264 .355 .202 .177 -.002 .248 -.109 -.280 .381 .342 
Alpha 
Numeric Easy 
 
.464 .160 .034 .174 .157 -.042 .243 -.474 .068 .136 
Alpha 
Numeric 
Normal 
.208 .203 -.002 .387 .532 .086 .251 -.380 .047 .443 
* p<.05 
 
 
Table 7. Correlation between CES-D and Baseline Cardiovascular/Critline Measures 
Comparison 
 
Pearson 
Correlation 
P-
Value 
Heart Rate .259 0.417 
Mean Arterial Blood 
Pressure 
.486 0.109 
Hematocrit .199 0.607 
Relative Blood Volume -.584 0.099 
O2 Saturation -.361 .339 
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CHAPTER 5 
 
DISCUSSION 
 
 The principal finding of this study was that specific domains of cognitive function, 
primarily long term memory, and possibly short term memory, appear to decline over the course 
of a hemodialysis session.  This was demonstrated by a significant decline in the delayed recall 
of the International Shopping List Task, as well as a trend towards a significant decline in the 
immediate recall of the International Shopping List Task. Because MHD patients frequently 
receive important medical information and advice during their treatment, this reduction in 
memory could impact their ability to manage their health, so may be clinically significant.    
We also examined potential mechanisms for the change in cognitive function during HD 
by assessing changes in hemodynamic variables, as well as their correlation with changes in 
various cognitive measures.  It has been hypothesized that declines in cognitive function during 
HD treatment may be due in part to cerebral ischemia, and indeed we saw a trend for a reduction 
in MAP during an HD session that could influence cerebral hemodynamics.    Furthermore, we 
found correlations between the change in hematocrit and change in the International Shopping 
List Task and Delayed International Shopping List Task, and in relative blood volume and mean 
arterial blood pressure and depression measures.  These correlations suggest that changes in 
hemodynamic variables during a dialysis treatment may be related to the declines in cognitive 
function.  We speculate that interventions that influence hemodynamic changes during dialysis 
treatment could improve cognitive function, though this hypothesis needs to be thoroughly tested 
in future studies.   
The delayed recall of the International Shopping List Task tests verbal learning and long 
term memory (Home – Cogstate, 2015). This is an important domain of cognitive functioning for 
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dialysis patients since they get a large amount of their education on diet, exercise, medication, 
and their treatment during their sessions. If HD patients cannot remember this information 
beyond the timing of working memory, the consequences could be detrimental. The International 
Shopping List Task tests verbal learning and working memory (Home – Cogstate, 2015). Being 
that working memory is the act of remembering information for about 15-20 seconds, it is 
concerning that there was a trend towards significance for this Task. In today’s society, people 
tend to rely less on their memory and more on working of lists; these lists either being written 
down on paper or stored in a mobile device. This could theoretically explain the initial issue of 
remembering the items but does not account for the near significant dip in items as time 
progressed. 
We observed significance and a trend towards significance in performance during 2 of 5 
tasks measured by the CogState program. These tasks, the International Shopping List and the 
delayed version of this task, could not have a learning affect associated with them since the 
shopping lists change every time. There is no phase during the testing where the rules need to be 
learned, both mental and motor, and people are used to a list memorization task due to school or 
daily life. The other tasks have a variety of rules and motor aspects that need to be learned for 
optimal performance. For this testing, there would likely be a more accurate depiction of 
cognitive impairment and a significance shown if the patients could practice the tests before 
baseline testing. In this instance the baseline testing acted as a practice session and may have 
decreased performance which would make the gap in performance between the baseline and 1 
hour testing sessions less. Lastly, there were only 12 participants tested in this pilot study. A 
larger sample size would have provided greater statistical power and possibly result in significant 
differences in performance on additional tasks. 
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Performance on the Count Battle testing did not show a decline over the course of a 
dialysis session. The Trails A/B tests give information regarding visual search speed, scanning, 
speed of processing, mental flexibility, as well as executive functioning (Arnett & Labovitz, 
1995). In general, this testing is the most inclusive since executive functioning is the overarching 
term for the control of cognitive processes, including working memory, reasoning, task 
flexibility, problem solving, planning, and execution. Like CogState, if a practice session was 
implemented prior to the baseline testing there would likely be more significance overall. This 
could apply more for this series of tests due to the far more complicated rules and motor 
functioning needed. For this testing, a max out time of 300 seconds was used in order to: 1) stay 
within the 15-20 minutes of testing at each time point; and 2) Decrease the burden on the 
patients. In this version of the Trails A/B, an incorrect answer would set the participant back one 
circle. So if one was at 12 and missed 13, the program would flash red and the participant would 
need to select 11 again. Often what occurred was that the participant would make an incorrect 
selection and not notice the red flash and would continue as normal. This would lead to multiple 
errors, sometimes going as far back as the initial selection of 1. In addition, when a max out 
occurred the participant would usually have been consistently making errors and ending up near 
the beginning of the test. Due to this, the 300 seconds may not be truly capturing the 
participant’s times. To counteract this, number of errors should be factored into the analysis to 
truly illustrate what occurred or the error causing a regression in progress should be removed.  
 The primary measures that were collected for the cardiovascular portion of testing 
consisted of heart rate and mean arterial pressure. As expected, there was no change in heart rate,  
but there was a trend for a reduction in MAP. Since MAP gives an indication of the mean 
perfusion pressure across the entire cardiac cycle, one could assume that the organs and tissues 
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of the body are experiencing hypoperfusion, or low blood flow. This is an important finding 
since a high proportion of the proposed mechanisms revolve around vascular issues leading to 
inadequate oxygenation of the brain (Pereira et al., 2005). To get a clearer picture of the blood 
flow in the brain it would be beneficial to use techniques that may give an image of what is 
happening in the brain during dialysis as these tests are being performed. This may include MRI, 
Transcranial Doppler Imaging, electroencephalography, or an OxiplexTS. The Oxiplex TS is a 
novel, non-invasive, way to monitor tissue oxygenation and hemoglobin concentration. By using 
this technology, one could better associate brain oxygenation to cognitive functioning with a 
more direct approach. 
 Multiple correlations were run across all the data presented here along with 
questionnaires measuring quality of life, the KD-QoL, and depression, the CES-D. The KD-QoL 
has multiple domains that it analyzes but the only one that showed significance was the one 
associated with ability to work. This measure lacks the ability to give a specific reason why the 
participant is able to work outside of the obvious burdens of MHD. It is a logical step in the 
thought process, however, to think that a reduced cognitive state would contribute to an inability 
to perform and possibly keep a job. The CES-D showed that 33% of the participants were 
depressed. This is quite a high number but when correlated with the cognitive measures there 
was no significance. However, when the CES-D scores were compared to baseline mean arterial 
blood pressure significance was seen. The trend towards significance of the relative blood 
volume and MAP help support this. It is well known that depression often follows measures of 
cognitive impairment (Peterson, 2013). This makes sense when delving further into the 
comparisons of the Critline and cognitive measures. The reduced perfusion of blood, shown by 
the MAP and BV measures, shows that lack of blood flow throughout the body is associated with 
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depression and cognition changes. It is necessary to look at this again once more data has been 
collected from a greater number of participants to see if significance is seen across more 
domains. 
 In summary, we found reductions in the cognitive domain of long term memory with near 
significant findings in working memory. We also found that executive functioning had no 
significance overall. In addition, a trend toward significance was found when looking at MAP 
measures over the course of a dialysis session. When correlated to the cognition measures, it was 
found that some ΔMAP values were highly associated. Lastly, quality of life measures pertaining 
to ability to work were correlated to cognitive measures and depression measures was correlated 
with relative mean arterial pressure; being supported by near significance in in relative blood 
volume and mean arterial blood pressure. Further research involving individuals on HD is 
needed to test if these findings hold up, if not grow larger, as the power increases. It would be 
very useful to use a technique to directly measure oxygenation and blood perfusion in the brain 
along with cognition measures to get a concrete idea of the mechanics behind cognitive 
impairment. To our knowledge, this is the first study that has assessed cognitive functioning as it 
declines across a single dialysis session using concise cognitive batteries via laptop and tablet. 
The novelty of this study and the reduction in patient burden that the methodology creates help to 
aid in the implications of these findings on future research. Ultimately, more research is needed 
however this study clearly shows that cognitive impairment is a pervasive issue in the MHD 
population that must be dealt with. 
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CHAPTER 6 
 
CONCLUSIONS 
 
A number of physiological changes occur during hemodialysis treatment including: 
vascular factors, cerebrovascular factors, oxidative stress, inflammation, anemia, parathyroid 
hormone effects, and erythropoietin deficiency, can have a detrimental effect on cognition as the 
session goes on. Of these, the shift in blood pressure and perfusion are amongst the most 
detrimental to the patient. As less blood gets to cerebral tissues, less oxygen gets delivered and 
neuronal activity is reduced, which ultimately leads to reduced functioning of various cognitive 
domains via apoptosis and necrosis. Results from this study indicate the presence of cognitive 
impairment and correlation between changes in blood pressure and changes in cognitions. 
 Specifically we found that during hemodialysis treatment: 
 Long-term memory is reduced 
 There is a trend for a reduction in Mean Arterial Pressure 
 Changes in cognitive measures and MAP are correlated 
 Cognitive measures and ability to work are correlated 
 There is a trend in relative blood volume and mean arterial blood pressure when 
correlated with depression measures as well as change in hematocrit when 
correlated with changes in memory measures 
We have shown that from a technical standpoint: 
 It is possible to capture cognitive impairment across a single dialysis session 
 It is possible to use newer, computer and tablet based-technology to capture 
these changes; aside from the traditional paper and pen methods that take longer 
and have higher patient burden 
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Overall, these data suggest that there is cognitive impairment in the HD population and 
that there is a correlation between blood pressure and the cognitive changes as well as depression 
and changes in blood flow. In addition, the testing measures selected for this study were sensitive 
enough to detect the cognitive changes while minimizing time and patient burden. This study is a 
stepping stone for future studies that will use more participants to hopefully show an even larger 
impact on cognition. Future studies may be able to use these techniques to measure cognition while 
taking steps to alleviate the impairment that is occurring. 
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